Caliway Biopharmaceuticals Co., Ltd. (TPE:6919)
Taiwan · Delayed Price · Currency is TWD 102.50
-2.00 (-1.91%)
Aug 19, 2026, 1:30 PM CST
TPE:6919 Revenue
Caliway Biopharmaceuticals had revenue of 3.57M TWD in the quarter ending June 30, 2026, a decrease of -70.80%. This brings the company's revenue in the last twelve months to 29.39M, down -34.44% year-over-year. In the year 2025, Caliway Biopharmaceuticals had annual revenue of 38.04M, down -14.40%.
Revenue (ttm)
29.39M
Revenue Growth
-34.44%
P/S Ratio
5,529.86
Revenue / Employee
n/a
Employees
n/a
Market Cap
162.54B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 38.04M | -6.40M | -14.40% |
| Dec 31, 2024 | 44.43M | 5.50M | 14.13% |
| Dec 31, 2023 | 38.93M | 26.11M | 203.68% |
| Dec 31, 2022 | 12.82M | 481.00K | 3.90% |
| Dec 31, 2021 | 12.34M | 1.99M | 19.22% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sunmax Biotechnology | 2.04B |
| EirGenix | 1.13B |
| Ever Supreme Bio Technology | 1.08B |
| TaiMed Biologics | 619.49M |
| Medigen Vaccine Biologics | 573.85M |
| Oneness Biotech | 153.78M |
| ACRO Biomedical | 52.76M |
| Lumosa Therapeutics | 34.37M |
Caliway Biopharmaceuticals News
- 2 months ago - Caliway Biopharmaceuticals Quarterly report: Q1 2026 - Filings
- 3 months ago - Caliway Biopharmaceuticals Slides: Investor presentation - Filings
- 4 months ago - Caliway Biopharmaceuticals Quarterly report: Q4 2025 - Filings
- 8 months ago - Caliway Biopharmaceuticals Quarterly report: Q3 2025 - Filings
- 11 months ago - Caliway Biopharmaceuticals Quarterly report: Q2 2025 - Filings